Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 48 Published: April 04, 2022 Report Code: GDGMDHC22085TDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    https://www.ispeech.org/text.to.speech

Neuronal acetylcholine receptor subunit beta-2 (CHRNB2) is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor and results in extensive change in conformation. This affects all subunits and leads to the opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The CHRNB2 pipeline market research report provides comprehensive information on CHRNB2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key Mechanisms of Action in the CHRNB2 Pipeline Products Market

The key mechanisms of action in the CHRNB2 pipeline products market are Neuronal Acetylcholine Receptor Subunit Beta 2 Agonist and Neuronal Acetylcholine Receptor Subunit Beta 2 Antagonist.

CHRNB2 Pipeline Products Market Analysis by Mechanisms of Action

CHRNB2 Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the CHRNB2 Pipeline Products Market

The key route of administration in the CHRNB2 pipeline products market is oral.

Key Molecule Types in the CHRNB2 Pipeline Products Market

The key molecule type in the CHRNB2 pipeline products market is small molecule.

Major Companies in the CHRNB2 Pipeline Products Market

The major companies in the CHRNB2 pipeline products market are Ctcbio Inc, Sobrera Pharma AB, Sopharma AD, and Suven Life Sciences Ltd.

CHRNB2 Pipeline Products Market Report Overview

Key Mechanisms of Action Neuronal Acetylcholine Receptor Subunit Beta 2 Agonist and Neuronal Acetylcholine Receptor Subunit Beta 2 Antagonist
Key Routes of Administration Oral
Key Molecule Type Small Molecule
Major Companies Ctcbio Inc, Sobrera Pharma AB, Sopharma AD, and Suven Life Sciences Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

Ctcbio Inc

Sobrera Pharma AB

Sopharma AD

Suven Life Sciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Overview

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Companies Involved in Therapeutics Development

Ctcbio Inc

Sobrera Pharma AB

Sopharma AD

Suven Life Sciences Ltd

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Drug Profiles

(varenicline tartrate + bupropion hydrochloride) SR – Drug Profile

Product Description

Mechanism Of Action

History of Events

CDFF-0318 – Drug Profile

Product Description

Mechanism Of Action

History of Events

cytisinicline – Drug Profile

Product Description

Mechanism Of Action

History of Events

ropanicant [INN] – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders – Drug Profile

Product Description

Mechanism Of Action

varenicline tartrate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Dormant Products

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Discontinued Products

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Ctcbio Inc, 2022

Pipeline by Sobrera Pharma AB, 2022

Pipeline by Sopharma AD, 2022

Pipeline by Suven Life Sciences Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..2)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Route of Administration and Mechanism of Actions, 2022

Number of Products by Molecule Type and Mechanism of Actions, 2022

Frequently Asked Questions

The key mechanisms of action in the CHRNB2 pipeline products market are Neuronal Acetylcholine Receptor Subunit Beta 2 Agonist and Neuronal Acetylcholine Receptor Subunit Beta 2 Antagonist.

The key route of administration in the CHRNB2 pipeline products market is oral.

The key molecule type in the CHRNB2 pipeline products market is small molecule.

The major companies in the CHRNB2 pipeline products market are Ctcbio Inc, Sobrera Pharma AB, Sopharma AD, and Suven Life Sciences Ltd.

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.